Sponsor of the Day:
Jerkmate
https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent...
Jul 7, 2025 - TORONTO, May 12, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
provides updateresearch studynerve agentrevivetherapeutics
https://jaims.in/jaims/article/view/5796
A Prospective Pilot Study Evaluating the Efficacy and Safety of Jeevan Sanjeevini Kadha in...
pilot studyprospectiveevaluatingefficacysafety
https://www.einpresswire.com/article/675077467/stroke-survivors-and-healthy-volunteers-needed-to-participate-in-dallas-fort-worth-study-evaluating-wearable-device
Stroke Survivors and Healthy Volunteers Needed to Participate in Dallas-Fort Worth Study Evaluating...
Dec 14, 2023 - Alva Health, Inc., a medical device startup developing a wearable device to recognize patterns indicative of stroke, in collaboration with the Brain Injury
dallas fort worthstroke survivorshealthy volunteersstudy evaluatingneeded
https://medicine.yale.edu/cancer/trial/a-phase-1-study-of-bg-75098-alone-and-in-combo-with-other-agents/
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics,...
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and
open label studyphase1a1bevaluating